Rasagiline Added to Aricept in Patients With Mild to Moderate Alzheimer's Disease

- Dementia | Alzheimer's Disease
- Completed

Study Title: Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)

Teva Identifier: TVP-1012-A001-201

ClinicalTrials.gov Identifier: NCT00104273

Study Status: Completed

Trial Condition(s): Dementia | Alzheimer's Disease

Interventions: Drug: Rasagiline

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age group: Adult, Older Adult

Age Range: 45 Years to 90 Years

Trial Duration: 08/01/2004 - 01/00/1900

Phase: Phase 2

Study Type

Interventional